A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Latest Information Update: 26 Sep 2022
At a glance
Most Recent Events
- 06 Mar 2018 According to a Caladrius Biosciences media release, Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius is the principal investigator of the study
- 05 Dec 2014 New trial record